Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Income from Non-Controlling Interests (2016 - 2025)

Cumberland Pharmaceuticals' Income from Non-Controlling Interests history spans 16 years, with the latest figure at -$16950.0 for Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests fell 878.59% year-over-year to -$16950.0; the TTM value through Dec 2025 reached -$28583.0, down 290.27%, while the annual FY2025 figure was -$28583.0, 179.28% down from the prior year.
  • Income from Non-Controlling Interests for Q4 2025 was -$16950.0 at Cumberland Pharmaceuticals, down from -$8282.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $43791.0 in Q1 2024 and bottomed at -$36561.0 in Q4 2021.
  • The 5-year median for Income from Non-Controlling Interests is -$15768.5 (2022), against an average of -$12139.7.
  • The largest annual shift saw Income from Non-Controlling Interests surged 320.08% in 2024 before it crashed 878.59% in 2025.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$36561.0 in 2021, then surged by 48.07% to -$18985.0 in 2022, then grew by 26.67% to -$13921.0 in 2023, then soared by 115.64% to $2177.0 in 2024, then plummeted by 878.59% to -$16950.0 in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Income from Non-Controlling Interests are -$16950.0 (Q4 2025), -$8282.0 (Q3 2025), and $5533.0 (Q2 2025).